Physician profile
Hillary Sandlin Mitchell
NPI 1992161301
$10,098.82
in general payments reported to CMS, 2019-2025
18 companies · $33.13 in 2025
The $33.13 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $586 · 2023: $793 · 2024: $8,297 · 2025: $33.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,875 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,000 · Food and Beverage: $1,115 · Travel and Lodging: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,875.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,000.00 |
| Food and Beverage | $1,115.02 |
| Travel and Lodging | $132.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $8,276.50 | 2022-2024 | Auvelity |
| Alkermes, INC. | $406.14 | 2021-2024 | Aristada, Lybalvi |
| Abbvie INC. | $292.17 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $147.81 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $139.04 | 2021-2024 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $135.32 | 2022-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $135.22 | 2022-2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $119.03 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $83.88 | 2022-2024 | Quviviq |
| Harmony Biosciences LLC | $67.22 | 2023 | Wakix |
| Eisai INC. | $65.58 | 2021 | |
| Genentech USA, INC. | $62.44 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $55.63 | 2022-2023 | Uzedy |
| Intra-Sana Laboratories | $33.13 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Vanda Pharmaceuticals INC. | $27.24 | 2023 | Fanapt, Hetlioz |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.95 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $15.68 | 2022 | |
| Jazz Pharmaceuticals INC. | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.